Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.

@article{Carmona2009ControllingHR,
  title={Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.},
  author={Sergio Carmona and Michael R. Jorgensen and Soumia Kolli and Carol Crowther and Felix H Salazar and Patricia L. Marion and Masato Fujino and Yukikazu Natori and Maya Thanou and Patrick Arbuthnot and Andrew D. Miller},
  journal={Molecular pharmaceutics},
  year={2009},
  volume={6 3},
  pages={706-17}
}
Harnessing RNA interference (RNAi) to inhibit hepatitis B virus (HBV) gene expression has promising application to therapy. Here we describe a new hepatotropic nontoxic lipid-based vector system that is used to deliver chemically unmodified small interfering RNA (siRNA) sequences to the liver. Anti HBV formulations were generated by condensation of siRNA (A component) with cationic liposomes (B component) to form AB core particles. These core particles incorporate an aminoxy cholesteryl lipid… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…